[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Rare Diseases posts on X about dyne therapeutics, japan, oneyear, longterm the most. They currently have XXXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.
Social category influence stocks countries
Social topic influence dyne therapeutics, japan, oneyear, longterm, $abbv, people with, $4528t
Top assets mentioned Dyne Therapeutics, Inc. Common Stock (DYN) AbbVie Inc (ABBV)
Top posts by engagements in the last XX hours
"Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy - For More Information Visit @Dyne_tx #Duchenne #Muscular_Dystrophy #Rare_Diseases"
X Link @CheckOrphan 2025-09-29T16:28Z 18.1K followers, XXX engagements
"Rocket Pharmaceuticals Reports FDA Acceptance of BLA Resubmission for KRESLADI to Treat Severe Leukocyte Adhesion Deficiency-I (LAD-I) - For More Information Visit @RocketPharma #LAD_I #FDA #Rare_Diseases #OrphanDrugs #Drug_Research"
X Link @CheckOrphan 2025-10-15T15:00Z 18.1K followers, XX engagements
"CSL Vifor and Travere Therapeutics Highlight Inclusion of FILSPARI in Updated 2025 KDIGO Guidelines for IgA Nephropathy Treatment - For More Information Visit @CSL @TravereRare #Rare_Diseases #OrphanDrugs #IgANephropathy #IgAN #Drug_research"
X Link @CheckOrphan 2025-09-26T12:39Z 18.1K followers, XXX engagements
"NEJM Publishes Study Showing How Regenerons DB-OTO Restored Hearing in XX of XX Children with Profound Genetic Hearing Loss - For More Information Visit @Regeneron #Hearing_Loss #FDA #NEJM #Rare_Diseases #OrphanDrugs #Pediatrics"
X Link @CheckOrphan 2025-10-13T12:43Z 18.1K followers, XXX engagements
"Dyne Therapeutics Reports One-Year Data Showing Meaningful Functional Gains with Z-Basivarsen in Myotonic Dystrophy Type X (DM1) - For More Information Visit @Dyne_tx #DM1 #Rare_Diseases #Myotonic_Dystrophy #OrphanDrugs #Drug_research"
X Link @CheckOrphan 2025-10-07T15:11Z 18.1K followers, XXX engagements
"Ipsen Wins Japanese Approval for Bylvay to Treat Pruritus in Children with Rare Liver Disorder Progressive Familial Intrahepatic Cholestasis (PFIC) - For More Information Visit #Rare_diseases #PFIC #progressive_Familial_Intrahepatic_Cholestasis"
X Link @CheckOrphan 2025-09-19T13:48Z 18.1K followers, XXX engagements
"Neurocrine Biosciences: INGREZZA Achieves Robust Symptomatic Remission in Tardive Dyskinesia Patients in KINECT-PRO Phase X Study - For More Information Visit @neurocrine #INGREZZA #Rare_Diseases #OrphanDrugs #Tardive_Dyskinesia #Drug_Research"
X Link @CheckOrphan 2025-09-23T13:02Z 18.1K followers, XXX engagements
"argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - For More Information Visit @argenxglobal #MyastheniaGravis #FDA #Rare_Diseases #OrphanDrugs #Drug_Discovery #VYVGART"
X Link @CheckOrphan 2025-08-25T14:21Z 18.1K followers, XXX engagements
"Neurocrine Biosciences Reports Three-Year Data Showing Sustained Chorea Improvement and Long-Term Safety of INGREZZA in Huntingtons Disease - For More Information Visit @neurocrine #HuntingtonDisease #Rare_Diseases #OrphanDrugs"
X Link @CheckOrphan 2025-10-06T13:45Z 18.1K followers, XXX engagements
"AbbVie Submits Biologics License Application to FDA for Pivekimab Sunirine (PVEK) in Rare Blood Cancer BPDCN - For More Information Visit @abbvie #Rare_diseases #Blood_Cancer #BPDCN"
X Link @CheckOrphan 2025-10-01T14:19Z 18.1K followers, XXX engagements
"Novo Nordisk Submits Biologics License Application (BLA) to FDA for Mim8; An Investigational Prophylaxis Treatment for People with Hemophilia A with or without Inhibitors - For More Information Visit @novonordisk #Hemophilia #Rare_diseases"
X Link @CheckOrphan 2025-09-29T14:24Z 18.1K followers, XXX engagements
"Ono Pharmaceutical Reports Positive Interim Phase X Results for ONO-2808 in Multiple System Atrophy (MSA) - For More Information Visit @Ono_pharma_PR #Multiple_System_Atrophy #MSA #Rare_Diseases #OrphanDrugs #Drug_Research #Ono_pharma"
X Link @CheckOrphan 2025-10-10T14:19Z 18.1K followers, XXX engagements
"FDA Approves Regenerons Libtayo as First Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) - For More Information Visit @Regeneron #CSCC #Rare_Diseases #FDA #Squamous_Cell_Carcinoma #OrphanDrugs #Libtayo"
X Link @CheckOrphan 2025-10-09T12:06Z 18.1K followers, XXX engagements